Abstract 290P
Background
The presence of residual disease (RD) after NAT is correlated with a poor outcome in EBC patients. New strategies are required to early identify patients who will not achieve a pathological complete response (pCR). Metabolomics may represent an innovative technology to identify host-related factors correlated with treatment outcome. In this study, we evaluated the predictive ability of metabolomics combined with machine learning in EBC patients receiving NAT.
Methods
Untargeted metabolomic analysis was performed in EBC patients candidates for NAT at our institution. Plasma samples were collected at baseline, before start of treatment. Small molecules were extracted, derivatized and then analysed using bi-dimensional gas chromatography/mass spectrometer (GCxGC-MS). The metabolomic profiling was then evaluated according to response to therapy (pCR versus RD). A machine learning approach was implemented with Boruta features selection algorithm combined with genetical algorithm as classifier, on a training set of 69 samples and validated on the remaining 27.
Results
From 12/2020 to 05/2023, 109 EBC patients have been enrolled (26 ER+, 45 HER2+, 38 TN); surgery was performed in 96 patients so far, with an overall pCR of 51% (ER+ 19%, HER2+ 51%, TN 55%). 61 small molecules were expressed (p<0.05 and Fold Change FC >1.3) between patients in pCR or RD. By multivariate analysis patients with RD showed higher levels of unsaturated fatty acids, as eicosatrienoate (FC=6), 9-decenoic acid (FC=2.2) and 17-octadecynoic acid (FC=2.2) and lower levels of fatty acids, as hexadecenoic acid (FC >100), doconexent (FC=69.5), 9,11-conjugated linoleic acid (FC=5.2), circulating glucose (FC=71) and glucopyranose (FC=23). Pathway analysis revealed the involvement of amino and fatty acid metabolism. A prediction model, combining metabolomics and machine learning, was implemented on 35 metabolomic probes and correctly identified the type of response with an accuracy of 95%.
Conclusions
Our data indicate that host-related metabolomic signatures may identify patients with EBC failing to achieve a pCR after NAT. We identified several fatty acids, amino acids and small molecules that can be modulated through diet. Possible effects by BC subtype are being investigated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Gennari.
Funding
AIRC.
Disclosure
A. Gennari: Other, Advisory Board: Roche, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
314P - Concordance of somatic variants between circulating tumor DNA and tissue in patients with breast cancer
Presenter: Kangsu Shin
Session: Poster session 02
315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Presenter: Sarah Powell
Session: Poster session 02
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
318P - Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Presenter: Ryota Otsubo
Session: Poster session 02
319P - The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
Presenter: Yumiko Koi
Session: Poster session 02
320P - Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Presenter: Mariia Ivanova
Session: Poster session 02
321P - Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Presenter: Dione Aguilar
Session: Poster session 02
322P - Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Presenter: Shusen Wang
Session: Poster session 02
323P - Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Presenter: Felicitas Schneider
Session: Poster session 02